Purple Biotech Reports Third Quarter 2023 Financial
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24...
Source: globenewswire.com
Unaudited Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Unaudited Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Unaudited Statement Today - Breaking & Trending Today
Purple Biotech Reports Second Quarter 2023 Financial Results
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...
Source: marketscreener.com
Purple Biotech Reports Second Quarter 2023 Financial
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies...
Source: globenewswire.com
Clovis Oncology : Modification to Rights of Security Holders
Research and Development - General and Administrative 4,321,718 431,103 52,148 Selling Expenses 228,165 13,808-Operating Taxes 28,649 - Other Operating Expenses -- Total Operating Expenses 3,314,185...
Source: marketscreener.com
Clovis Oncology : Regulation FD Presentation - Form 8-K
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor § Jointly Administered... | June 10, 2023
Source: marketscreener.com